Arcutis to Present at Upcoming Investor Conference
12 avr. 2023 16h45 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 avr. 2023 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
05 avr. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Eight additional national and regional health plans are now covering ZORYVE for plaque psoriasisZORYVE is a once-daily, steroid-free cream approved for use in both adults and adolescents with plaque...
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
18 mars 2023 07h00 HE
|
Arcutis Biotherapeutics, Inc.
New INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream 0.15%Rapid and significant improvements were...
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
09 mars 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national survey insights depicting disease burden, path to diagnosis...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mars 2023 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
28 févr. 2023 16h02 HE
|
Arcutis Biotherapeutics, Inc.
Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growthSecured expanded commercial...
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
21 févr. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam would be the first topical drug for seborrheic...
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
08 févr. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Quarterly investor conference call and webcast scheduled for Tuesday, February 28 at 4:30 p.m. ETArcutis management will also participate in the Cowen 43rd Annual Healthcare Conference in March ...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 févr. 2023 16h10 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...